Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models

(2014) Kathleen R Whiteman et al.   mAbs

Relapsed small cell lung cancer: treatment options and latest developments

(2014) Nobuhiro Asai et al.   Therapeutic Advances in Medical Oncology

Numbers and cytotoxicities of CD3+CD56+T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia

(2013) Wenjian Guo et al.   CANCER BIOLOGY & THERAPY

Trastuzumab Emtansine: First Global Approval

(2013) Anita Ballantyne et al.   DRUGS

ADME of Antibody–Maytansinoid Conjugates

(2012) Hans K. Erickson et al.   AAPS Journal

Merkel cell carcinoma: high recurrence rate despite aggressive treatment

(2012) Michael C. Soult et al.   JOURNAL OF SURGICAL RESEARCH